Objectives
At diagnosis, 30% of patients with pancreatic cancer are unresectable stage 3 locally advanced. The standard treatment for locally advanced pancreatic cancer (LAPC) is not defined. The current study was conducted to assess the roles of chemotherapy and chemoradiation for LAPC treatment.
Methods
Between June 2006-March 2011, 100 patients with LAPC were treated at Johns Hopkins Hospital. Retrospective analysis was performed to compare cumulative incidence of progression (CIP) and overall survival (OS) among different subgroups.
Results
For the 100 patients, median OS was 15.8 months and median CIP 8.4 months. The combination of chemotherapy and chemoradiation prior to disease progression was significantly associated with improved CIP (p=0.001) and improved OS when compared to chemoradiation alone (median OS 16.4 vs. 11.1 mo; p=0.03). Among patients receiving combination treatment, patients who received chemotherapy first followed by chemoradiation had a trend towards lower CIP (p=0.09) and improved OS (median OS: 18.1 vs. 11.0 mo, p=0.09). Patients who received >2 cycles of chemotherapy prior to chemoradiation had a significantly decreased CIP (p=0.008) and a trend toward better OS (median OS 19.4 vs. 15.7 mo, p=0.10). On multivariate analysis, receiving >2 cycles of chemotherapy prior to chemoradiation was associated with improved CIP.
Conclusions
While combination chemotherapy and chemoradiation is favored in the treatment of LAPC, longer induction chemotherapy may play a more important role in sensitization of tumors to subsequent chemoradiation. Our results support treating patients with induction chemotherapy for at least 3 cycles followed by consolidative chemoradiation. These results merit further validation by a prospective study.